MedTrace Logo

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

NCT01934166 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-11-08

No results posted yet for this study

Summary

To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene

Conditions

  • Renal Impairment

Interventions

DRUG

Nalmefene 18 mg

One single oral dose of 18 mg

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01934166 on ClinicalTrials.gov